Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=5034
Microfluidic immunoassay or lab-on-a-chip consists of miniaturization of conventional laboratory operations, including reagent loading, reaction, separation, and detection on the microchip. Traditional immunoassays depend on large and costly equipment and skilled professionals, with low sensitivity, complex operation, long assay time, and expensive reagents. Furthermore, with the increasing demand for real-time detection in clinical diagnostics, the need for highly sensitive, portable, enhanced accuracy, rapid immunoassay methods are also increasing.
The growth of this market is driven by the increasing use of microfluidic immunoassays in drug discovery & development and biomarker detection, the advantages of lab-on-chip immunoassays over conventional immunoassays, pharmaceutical & biotechnology companies' increasing focus on research & development, and the miniaturization of biological and chemical assays. However, bubble formation and dead volume in microfluidics devices restrain the growth of this market.
Moreover, the increasing demand for point-of-care diagnostics and recent advancements in microfluidic immunoassay technology are expected to generate market growth opportunities. However, the selection of suitable substrate materials for designing microfluidic chips and product design and cost-related limitations in developing countries are major challenges for market stakeholders.
Increasing Benefits of Microfluidic Immunoassay Over Conventional Immunoassay is Driving the Market Growth
The conventional immunoassay technologies used for diagnostic applications have many limitations. These immunoassays are required to be conducted on sophisticated instruments by trained professionals in hospital or commercial diagnostic laboratories. These instruments are costly and need higher capital investments. Further, the time from collecting patient samples to obtaining test results requires several days. This time lag might cause catastrophic consequences for patients. Further, current point of care devices available in the market offer qualitative or semi quantitative results or do not provide precise results.
Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=5034
The introduction of microelectromechanical systems (MEMS) and micro total analysis systems (μTAS) into clinical applications have revolutionized the process of disease diagnosis. The microfluidic devices (LOC) based on these technologies are changing the dynamics of clinical diagnosis. Diagnostic tests that are usually performed in a laboratory are now miniaturized on a single chip. It has led to enhanced efficiency by reducing turnaround time and mobility. Further, microfluidic detection does not need sample preparation. These devices are easily automated to perform routine assays on standardized chips with little human intervention. Compared to the conventional benchtop systems (that use milliliters of sample volume), microfluidic systems only use microliters of samples to perform the test. This not only reduces the costs of the reagents involved, but also makes it possible to carry out the diagnosis efficiently when only limited sample volume is available. Most of all, this technology provides precise quantitative results which was lacking with many conventional immunoassays. Owing to such benefits offered by LOC over conventional methods, they are likely to witness growing adoption in coming years.
The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.).
The global microfluidic immunoassay market is segmented by product, technology, application, and end user. The study also evaluates industry competitors and analyzes their market share at global and regional levels.
Based on product, the global microfluidic immunoassay market is segmented into consumables and systems. In 2024, the consumables segment is expected to account for the largest share of 69.6% of the microfluidic immunoassay market. Assay kits are pre-packaged sets of materials and reagents used for performing tests. These user-friendly diagnostic kits require minimal training, making them ideal for use in settings with limited access to trained laboratory personnel, particularly in rural or remote areas. The kits are also lightweight and compact, allowing easy transport and use in various settings, including clinics, hospitals, and field locations. The repeated use of consumables in microfluidic immunoassay and new product developments drive market growth.
Have Specific Research Needs? Request a Customized Report-
https://www.meticulousresearch.com/request-customization/cp_id=5034
Based on technology, the global microfluidic immunoassay market is segmented into electrochemical detection and optical detection. The electrochemical detection segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to the increasing use of electrochemical sensors in microfluidic immunoassay for biomolecule detection. Additionally, electrochemical biosensors used in microfluidic immunoassay have many advantages, including the ability to load multiple reagents at once to obtain more data, contributing to the highest CAGR of the segment.
Based on application, the global microfluidic immunoassay market is segmented into cardiology, infectious diseases, oncology, and other applications. In 2024, the cardiology segment is expected to account for the largest share of 53.5% of the microfluidic immunoassay market. The cardiology segment is further divided into single biomarker detection and multiplexed biomarker detection. The increasing use of microfluidic immunoassay for the detection of troponin (cTnI), Natriuretic Peptides (NPS), Creatine Kinase (CK-MB), D-Dimer, and Myoglobin to detect acute myocardial infarction (AMI) is contributing to the largest share of the segment. The key players are also introducing microfluidic cartridges for the detection of troponin, further supporting the market share. For instance, in December 2022, QuidelOrtho Corporation (U.S.) received a Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test. This test is used for the diagnosis of myocardial infarction.
Based on end user, the global microfluidic immunoassay market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, hospitals, and other end users. The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR of 9.0% during the forecast period. The highest CAGR of the segment is attributed to pharmaceutical & biotechnology companies allocating significant resources to their research activities. Microfluidic immunoassay has become increasingly important in maintaining precision and accuracy in drug research and development and reducing the time required for research purposes. Numerous drug discovery processes can benefit from the use of microfluidic immunoassays, including drug screening, compound synthesis, delivery, and carrier manufacturing.
Geographically, in 2024, North America is expected to account for the largest share of 40.3% of the microfluidic immunoassay market. The North America microfluidic immunoassay market is estimated to be worth USD 387 million in 2024. The region's largest share is attributed to the high R&D expenditure, high prevalence of chronic diseases, growth in the pharmaceuticals industry, and large number of diagnostic and pathology laboratories for early diagnosis. The increasing healthcare expenditure has immensely impacted the development of laboratory diagnoses in the region. North America's per capita health expenditure reached USD 11,119.1 in 2021, increasing at a CAGR of 3.8% from 2017–2021 (source: The World Bank Group).
However, the Asia-Pacific microfluidic immunoassay market is slated to register the highest growth rate during the forecast period. The growth of the microfluidic immunoassay market in Asia-Pacific is attributed to the rising research funding in the healthcare and pharmaceutical industry, the rising number of research laboratories, the advancing research framework, and the growing number of diagnostic laboratories in countries such as China, India, Japan, South Korea, and others.
The report also includes an extensive assessment of the key strategic developments of leading market participants in the industry over the years (2021-2024). In the last couple of years, the global microfluidic immunoassay market witnessed several strategic developments.
Brows In-depth Report Now- https://www.meticulousresearch.com/product/microfluidic-immunoassay-market-5034
Scope of the Report:
Microfluidic Immunoassay Market Assessment, by Product
Microfluidic Immunoassay Market Assessment, by Technology
- Electrochemical Detection
- Optical Detection
Microfluidic Immunoassay Market Assessment, by Application
- Cardiology
- Single Biomarker Detection
- Multiplex Biomarker Detection
- Infectious Diseases
- Oncology
- Other Applications
Note: Other applications consist of pregnancy, diabetes, thyroid, kidney diseases, and drug of abuse testing
Microfluidic Immunoassay Market Assessment, by End User
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Hospital
- Other End Users
Note: Other end users include home healthcare, self-testing, academic institutes & research centers, and forensic labs
Microfluidic Immunoassay Market Assessment, by Geography
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of Asia-Pacific (RoAPAC)
- Latin America
- Middle East & Africa
Unlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/80588586
Related Reports:
Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User - Global Forecast to 2030
In-vitro Diagnostics (IVD) Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030
High Throughput Screening Market by Technology (Cell-based Assays [2D, 3D], Label-free, Lab-on-chip), Offering (Reagents, Liquid Handling, Readers, Sample Prep), Application (Target Identification, Toxicology, Stem Cell), End User - Global Forecast to 2031
Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Efficacy, Validation, Safety) Mechanism (Genetic, Epigenetic, Proteomic) Technology (ELISA, Microarray, PCR, NGS), Offering, Application, Disease Type, End User – Global Forecast to 2031
Related Blogs:
Top 10 Companies in Microfluidic Immunoassay Market
Microfluidic Immunoassay: The Emerging Lab-on-Chip Technology
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/246/microfluidic-immunoassay-market-2031
Photo: https://mma.prnewswire.com/media/2417996/Microfluidic_Immunoassay_Market.jpg
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
Share this article